Sign in
Taking people in United StatesPhase 2

Two-step transplant with radiation before stem cell transplant for blood cancers

Tests a two-step, lower-intensity radiation and chemotherapy preparation before stem cell transplant in blood cancers.

Key facts

Who runs it
Thomas Jefferson University
Where
Philadephia, United StatesSee the site
Trial code
Registry title
Two Step Haplo With Radiation Conditioning
Status
Recruiting
Phase
Phase 2
People taking part
63 people, planned
Started
25 Oct 2021
Expected to end
Apr 2032
Type of study
Interventional, 3 groups
Treatments tested
  • Fludarabine
  • Total-Body Irradiation
  • Donor Lymphocyte Infusion
  • Cyclophosphamide
  • Tacrolimus
  • Mycophenolate Mofetil
  • Hematopoietic Cell Transplantation
  • Melphalan
  • Bone Marrow Aspiration and Biopsy
  • Diagnostic Imaging
  • Biospecimen Collection
Record updated
30 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a blood cancer or related blood disease who need a stem cell transplant from a half-matched family donor or an identical related donor. It tests a two-step, lower-intensity preparation before the transplant.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Blood cancers such as acute myeloid leukemia, acute lymphoid leukemia in remission, myelodysplasia, chronic lymphocytic leukemia, multiple myeloma, chronic myeloid leukemia, myelofibrosis, Hodgkin and non-Hodgkin lymphoma, aplastic anemia, and other blood diseases where a transplant could remove the disease. People with chronic lymphocytic leukemia or T cell lymphoma can join if lymph node disease is none, minimal or not significant.
Earlier treatment
Some people who cannot have the usual strong transplant preparation can join, for example after earlier radiation therapy or after an earlier high-dose transplant preparation.
Biomarker or test result
Needs a donor with one haplotype mismatch, or an HLA identical related donor. Heart, lung, liver and kidney tests must meet set limits: left ventricular ejection fraction of 50% or more, diffusion lung capacity of oxygen and forced expiratory volume at 1 second of 50% or more of predicted, serum bilirubin of 1.8 or less, AST or ALT of 2.5 x upper limit of normal or less, creatinine clearance of 60 mL/min or more.

Main reasons for not taking part

  • Another cancer, except a skin cancer treated only locally
  • HIV positive
  • Cancer active in the central nervous system
  • Pregnant or breastfeeding
  • Life expectancy under 6 months for reasons other than the blood disease

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Radiation-based cohort diagnoses:; Acute myeloid leukemia; Acute lymphoid leukemia in remission; Myelodysplasia (MDS); Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement; Multiple myeloma; Chronic myeloid leukemia; Myelofibrosis; Myeloid malignancy not otherwise specified; Chronic myelomonocytic leukemia; Essential thrombocytopenia or polycythemia vera; T cell leukemia; T cell lymphoma without significant lymph node disease burden; Any hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable; Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen; Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)
  • Chemotherapy-based cohort diagnoses:; Hodgkin or non-Hodgkin lymphoma; Small lymphocytic lymphoma/CLL; Any other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease; Hematological malignancy in patients who cannot receive > 2 Gy radiation; Aplastic anemia and other non-malignant hematologic dyscrasias; Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)
  • Human leukocyte antigen (HLA) identical cohort diagnoses:; Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included)
  • Left ventricular ejection fraction of >= 50%
  • Diffusion lung capacity of oxygen >= 50% and forced expiratory volume at 1 second >= 50% of predicted corrected for hemoglobin
  • Serum bilirubin =< 1.8
  • Aspartate aminotransferase or alanine aminotransferase =< 2.5 x upper limit of normal
  • Creatinine clearance of >= 60 mL/min
  • Patients must have adequate Karnofsky performance status (KPS) and Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) scores:; Patients < age 60 years must have a KPS of >= 60% and an HCT-CI score of 5 or less; Patients aged 60 to 65 years must have a KPS of >= 60% and an HCT-CI score of 4 or less; Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less; Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less; (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator (PI) and at least 1 co-investigator (CI) not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities
  • Patients must be willing to use contraception if they have childbearing potential
  • Patient or patient's guardian is able to give informed consent
  • Patients should have a life expectancy of >= 6 months for reasons other than their underlying hematologic/oncologic disorder
  • Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
  • Patients should not be:; Human immunodeficiency virus positive; Have active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and/or a negative cerebral spinal fluid analysis
  • Pregnant or breastfeeding

Where in United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladephia, United StatesContact: Usama Gergis, MDTaking people

About the trial

What the trial wants to find out

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.

The 3 groups in the trial

  • Arm 1: Radiation-Based Cohort (fludarabine, TBI, infusion)Treatment being tested

    Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.

    Treatment: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, and Biospecimen Collection

  • Arm 2: Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)Treatment being tested

    Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.

    Treatment: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, and Biospecimen Collection

  • Arm 3: HLA- Identical cohort (radiation-based or chemotherapy-based conditioning)Treatment being tested

    This group (HLA- Identical cohort), which is expected to be small, can undergo HSCT with radiation-based or chemotherapy-based conditioning. Due to small numbers of patients with available HLA identical related donors, this third, descriptive arm is included so that this group, too small in number for a free-standing study, are treated on clinical trial. This is also a separate arm of the study and the outcome of patients treated on this arm will be analyzed descriptively without statistical comparison or power analysis.

    Treatment: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, and Biospecimen Collection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
Plain-language title
Two-step transplant with radiation before stem cell transplant for blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 October 2025